According to Bloomberg Markets, pharmaceutical company AbbVie Inc. has initiated a $10 billion investment-grade bond sale as part of its financing strategy for the pending acquisition of fellow drugmaker Apogee Therapeutics Inc. The debt offering represents a significant capital raise from the public markets to support the transaction.
The bond sale underscores AbbVie's continued reliance on favorable credit conditions to fund strategic M&A activity in the pharmaceutical sector. By accessing the investment-grade debt markets, the company is securing long-term financing at potentially attractive rates to complete its acquisition of Apogee.
This financing move demonstrates the robust demand for high-quality corporate debt and reflects investor confidence in AbbVie's creditworthiness and ability to integrate acquisitions while managing its debt profile.